As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
6 Analysts have issued a Coeptis Therapeutics forecast:
6 Analysts have issued a Coeptis Therapeutics forecast:
| Dec '23 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -20 -20 |
-
|
|
| EBIT (Operating Income) EBIT | -21 -21 |
67%
67%
|
|
| Net Profit | -21 -21 |
69%
69%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.
| Head office | United States |
| CEO | David Mehalick |
| Employees | 6 |
| Founded | 2017 |
| Website | coeptistx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


